Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2600115972) titled 'Efficacy and Safety of Becotatug Vedotin (EGFR ADC) plus Pucotenlimab and Cisplatin as Neoadjuvant Therapy for LA-HNSCC' on Jan. 4.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Condition:
Squamous cell carcinoma of the head and neck
Recruitment Status: Not Recruiting
Phase: 0
Date of First Enrollment: 2026-01-05
Target Sample Size: Test group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=303260
Published by HT Digital Content Services with permissio...